holding glp 1 prior to surgery Study Challenges Seven-Day Hold on GLP-1 Agonists Before The American Society of Anesthesiologists

Broadening Out vs

Reduced expression of mitochondrial frataxin in mice exacerbates diet-induced obesity

Guidelines for the management of thyroid cancer

The microglial density increases in the temporal and frontal lobes and region-dependent enlargement of microglial cell bodies in SCZ patients (Gober et al., 2022

Nanotechnology is another frontier in ICH therapy

Abstract Background and Aims: Incretin-based therapies, including glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, are essential treatments in diabetes management due to their efficacy in glycemic control and the additional benefits of GLP-1 RAs, which include cardiovascular and renal protection